Overview
Bayer Links
Investor Relations
News
January 28, 2010
Idiotype vaccination in the treatment of non-Hodgkin’s lymphoma
Bayer starts clinical Phase I study with personalized vaccine from tobacco plants
Leverkusen. The transfer into clinical development of a patient-specific vaccine represents a milestone for Bayer Innovation GmbH. Following approval of the Phase I study by the FDA (Food & Drug Administration) in the United States, the vaccine is now being tested in human subjects. » more
Idiotype vaccination in the treatment of non-Hodgkin’s lymphoma
Bayer starts clinical Phase I study with personalized vaccine from tobacco plants
Leverkusen. The transfer into clinical development of a patient-specific vaccine represents a milestone for Bayer Innovation GmbH. Following approval of the Phase I study by the FDA (Food & Drug Administration) in the United States, the vaccine is now being tested in human subjects. » more
November 11, 2009
Personalized therapy - a new therapeutic strategy to combat lymph node cancer
The Y-strategy: fighting cancer with tobacco
The human immune system is a perfectly coordinated team of specialized cells and signal molecules – a kind of bio-police force that is always at work tracking down intruders such as viruses, bacteria and foreign protein molecules and rendering them harmless. However, if individual parts of the defense system itself fall ill, a life-threatening and until now largely untreatable form of cancer known as non-Hodgkin’s lymphoma (NHL) can develop. » more
Personalized therapy - a new therapeutic strategy to combat lymph node cancer
The Y-strategy: fighting cancer with tobacco
The human immune system is a perfectly coordinated team of specialized cells and signal molecules – a kind of bio-police force that is always at work tracking down intruders such as viruses, bacteria and foreign protein molecules and rendering them harmless. However, if individual parts of the defense system itself fall ill, a life-threatening and until now largely untreatable form of cancer known as non-Hodgkin’s lymphoma (NHL) can develop. » more
Thursday, April 23, 2009
Start of clinical trial for Bayer’s new silica gel wound dressing
New hope in treatment of chronic wounds
Leverkusen. They say that time heals all wounds. Unfortunately, this is not true. Many people have serious wounds which heal only very slowly, if at all. For chronic wounds such as this, Bayer Innovation GmbH (BIG) has developed a special wound dressing which is designed to speed up the healing process. » more
Start of clinical trial for Bayer’s new silica gel wound dressing
New hope in treatment of chronic wounds
Leverkusen. They say that time heals all wounds. Unfortunately, this is not true. Many people have serious wounds which heal only very slowly, if at all. For chronic wounds such as this, Bayer Innovation GmbH (BIG) has developed a special wound dressing which is designed to speed up the healing process. » more
September 29, 2008
Cooperation with Kentucky Bioprocessing for future-oriented technology
Bayer broadens its manufacturing basis for biopharmaceuticals in tobacco plants
» more
Cooperation with Kentucky Bioprocessing for future-oriented technology
Bayer broadens its manufacturing basis for biopharmaceuticals in tobacco plants
» more
June 16, 2008
Pilot plant for future-oriented technology opens in Halle:
Bayer will use tobacco plants to produce medicines
First development candidate from the new plant for cancer indication non-Hodgkin’s lymphoma – Clinical phase I could start in 2009 / Bayer has invested over EUR 10 million in Halle since 2006. » more
Pilot plant for future-oriented technology opens in Halle:
Bayer will use tobacco plants to produce medicines
First development candidate from the new plant for cancer indication non-Hodgkin’s lymphoma – Clinical phase I could start in 2009 / Bayer has invested over EUR 10 million in Halle since 2006. » more
June 12, 2008
Research Cooperation with AmVac AG
Bayer Innovation GmbH is starting its research cooperation program with AmVac AG, a Swiss biopharmaceutical company based in Zug, on the development of a new influenza vaccine. Joint research and development work is beginning with the Bayer subsidiary Icon Genetics GmbH on a novel production approach. Antigens are to be produced for the first time in tobacco plants which along with AmVac AG’s adjuvant MALP-2 are to be developed into an efficient new generation of flu vaccines. » more
Research Cooperation with AmVac AG
Bayer Innovation GmbH is starting its research cooperation program with AmVac AG, a Swiss biopharmaceutical company based in Zug, on the development of a new influenza vaccine. Joint research and development work is beginning with the Bayer subsidiary Icon Genetics GmbH on a novel production approach. Antigens are to be produced for the first time in tobacco plants which along with AmVac AG’s adjuvant MALP-2 are to be developed into an efficient new generation of flu vaccines. » more
August 23, 2007
Plant Made Pharmaceuticals
In the future Tobacco plants could lead to better therapy for people with some forms of cancer that are difficult to treat. » watch film
Plant Made Pharmaceuticals
In the future Tobacco plants could lead to better therapy for people with some forms of cancer that are difficult to treat. » watch film
May 4, 2007
Technology of the Future from Bayer Innovation GmbH:
Rapid Healing with Novel Wound Dressings
Pilot plant for silica gel fibers to treat chronic wounds comes on stream
» more
Technology of the Future from Bayer Innovation GmbH:
Rapid Healing with Novel Wound Dressings
Pilot plant for silica gel fibers to treat chronic wounds comes on stream
» more
January 2007
DelSiTech signs License Agreement with Bayer Innovation
DelSiTech’s Proprietary DelSiTech ® Drug Delivery Technology is paving the way for Wound Care Business
» more
DelSiTech signs License Agreement with Bayer Innovation
DelSiTech’s Proprietary DelSiTech ® Drug Delivery Technology is paving the way for Wound Care Business
» more
Bookmark this page
E-mail this page
Advanced Search
